Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Deep brain stimulation is known to treat the symptoms of stiffness, slow movement, and tremor in people with Parkinson’s disease. Researchers are now a step closer to understanding exactly how this electrical stimulation of specific areas in the brain works.

Schematic illustration of ‘striatal damping’ by antidromic activation of striatopallidal axons. DA, dopaminergic; SNpc, substantia nigra pars compacta © James Fitzgerald
Schematic illustration of ‘striatal damping’ by antidromic activation of striatopallidal axons. DA, dopaminergic; SNpc, substantia nigra pars compacta

It is thought that part of the underlying problem for people with Parkinson’s is the overactivity of certain nerve cells. This overactivity affects the way that information flows from one circuit within the brain to another. In a paper published in the Journal of Neuroscience, researchers describe an experiment using deep brain stimulation that has demonstrated how the technique improves information flow between circuits, probably by calming down the overactive cells.

The researchers tested eye movements in 14 patients and 10 healthy controls. They electrically stimulated an area of the brain called the globus pallidus interna. They showed that this deep brain stimulation partially reverses deficits in voluntary control of eye movements, restoring some control.

This is an exciting finding because it suggests that deep brain stimulation might be able to address some of the non-motor aspects of Parkinson’s Disease
- Chrystalina Antoniades, lead author of the study.

The experiment showed improvement in information transfer between higher, cognitive, brain circuits and lower-level motor systems. This may mean that stimulation of the globus pallidus interna could have a positive effect on those symptoms of Parkinson’s disease that are not directly movement-related.

Read the paper online…

Read more about OcuLab…

Similar stories

Attention and memory deficits persist for months after recovery from mild COVID

Researchers from Oxford’s Nuffield Department of Clinical Neurosciences and Department of Experimental Psychology have shown that people who have had COVID but don’t complain of long COVID symptoms in daily life nevertheless can show degraded attention and memory for up to six to nine months.

New Academic Visitor from Nigeria

Associate Professor of Radiology, Godwin Ogbole has arrived on a six-month visit to the Nuffield Department of Clinical Neurosciences, as part of the Africa Oxford Initiative.

New spinout company: Human-Centric Drug Discovery

Human-Centric Drug Discovery is a new Oxford University spinout company from Professor Zameel Cader's lab.

Funding received for research into Motor Neuron Disease

A £210,000 donation from the Alan Davidson Foundation has been made to our Department to advance our world-leading research into Motor Neuron Disease. The funding will support a project manager to deliver an innovative research project using the genetic causes of MND to develop approaches to early diagnosis.

Research finds drug may benefit some patients hospitalised with COVID-19 pneumonia

A proof-of-concept trial involving Oxford researchers has identified a drug that may benefit some patients hospitalised with COVID-19 pneumonia.

Protein test could lead to earlier and better diagnosis of Parkinson’s

Scientists have observed the clumping of alpha-synuclein in the cerebrospinal fluid taken from people with Parkinson's. The findings offer hope that a pioneering new clinical test could be developed to diagnose Parkinson's correctly in its early stages.